SCHEMBL4447504

SCHEMBL4447504

ONc1ccc(-n2cncn2)c(F)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP3A4 P08684 1/20 0.57
BLM P54132 1/20 0.51
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
S1PR3 Q99500 2/20 0.41
POLB P06746 2/20 0.40
RAB9A P51151 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
MAPT P10636 1/20 0.39
S1PR1 P21453 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
AAK1 Q2M2I8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1485069 0.78 CYP3A4 (0.56) CYP1A2CYP2C9CYP2C19CYP3A4BLM
SCHEMBL7036622 0.76 CYP1A2 (0.54) CYP1A2CYP2C9CYP2C19CYP3A4BLM
SCHEMBL2896197 0.76 CYP1A2 (0.54) CYP1A2CYP2C9CYP2C19CYP3A4BLM
SCHEMBL2658961 0.76 CYP1A2 (0.54) CYP1A2CYP2C9CYP2C19CYP3A4BLM
SCHEMBL12490579 0.74 CYP1A2 (0.71) CYP1A2CYP2C9CYP2C19CYP3A4BLM
SCHEMBL14009298 0.73 CYP1A2 (0.54) CYP1A2CYP2C9CYP2C19CYP3A4BLM
SCHEMBL600179 0.73 CYP1A2 (0.69) CYP1A2CYP2C9CYP2C19CYP3A4BLM
SCHEMBL7831820 0.72 BLM (0.51) CYP1A2CYP2C9CYP2C19CYP3A4BLM
SCHEMBL1611931 0.72 ALDH1A1 (0.58) CYP1A2CYP2C9CYP2C19CYP3A4BLM
SCHEMBL14321518 0.72 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19CYP3A4BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550487-B2 Pyrrolidine-3,4-dicarboxamide derivatives HOFFMANN-LA ROCHE INC. (US) 2009-06-23 US disclosed
EP-1732918-B1 NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-11-12 EP disclosed
EP-1732918-A1 NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-20 EP disclosed
WO-2005092881-A1 NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-10-06 WO disclosed
US-20050215599-A1 Pyrrolidine-3,4-dicarboxamide derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215599-A1 Pyrrolidine-3,4-dicarboxamide derivatives F9, F2, F12 CYP1A2 563/4885CYP2C9 46/4885CYP2C19 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.